APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide and Oligonucleotide Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide and Oligonucleotide Drugs Market Outlook and Growth Opportunities 2026

29 December 2025202 pages

Choose your research edition.

Industry ResearchPeptide and Oligonucleotide Drugs Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide and Oligonucleotide Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Peptide and Oligonucleotide Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide and Oligonucleotide Drugs Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide and Oligonucleotide Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Peptide and Oligonucleotide Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide and Oligonucleotide Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide and Oligonucleotide Drugs market include Takeda, Sanofi, Novartis, Roche, Lilly, SciClone Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku and Moderna, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide and Oligonucleotide Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide and Oligonucleotide Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide and Oligonucleotide Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide and Oligonucleotide Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide and Oligonucleotide Drugs Segment by Company

Takeda

Sanofi

Novartis

Roche

Lilly

SciClone Pharmaceuticals

Sarepta Therapeutics

Nippon Shinyaku

Moderna

MiNA Therapeutics

Merck Serono

Ipsen PHarma Biotech

Ionis

Ferring Pharmaceuticals

BioNTech

AstraZeneca

Asahi Kasei

Alnylam

Peptide and Oligonucleotide Drugs Segment by Type

Oligonucleotide Drugs

Peptide Drugs

Peptide and Oligonucleotide Drugs Segment by Application

Oncology Drugs

Digestive system Drugs

Immunomodulatory Drugs

Bone and Connective Tissue Types

Other

Peptide and Oligonucleotide Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide and Oligonucleotide Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peptide and Oligonucleotide Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide and Oligonucleotide Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide and Oligonucleotide Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide and Oligonucleotide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide and Oligonucleotide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide and Oligonucleotide Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide and Oligonucleotide Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide and Oligonucleotide Drugs industry.

Chapter 3: Detailed analysis of Peptide and Oligonucleotide Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peptide and Oligonucleotide Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peptide and Oligonucleotide Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide and Oligonucleotide Drugs Industry Trends Table 2. Peptide and Oligonucleotide Drugs Industry Drivers Table 3. Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges Table 4. Peptide and Oligonucleotide Drugs Industry Restraints Table 5. Global Peptide and Oligonucleotide Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide and Oligonucleotide Drugs Revenue Share by Company (2021-2026) Table 7. Global Peptide and Oligonucleotide Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Peptide and Oligonucleotide Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Peptide and Oligonucleotide Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Peptide and Oligonucleotide Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peptide and Oligonucleotide Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Peptide and Oligonucleotide Drugs Company, Product Type & Application Table 13. Global Peptide and Oligonucleotide Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide and Oligonucleotide Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oligonucleotide Drugs Table 18. Significant Companies of Peptide Drugs Table 19. Global Peptide and Oligonucleotide Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Peptide and Oligonucleotide Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Peptide and Oligonucleotide Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Peptide and Oligonucleotide Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Peptide and Oligonucleotide Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Peptide and Oligonucleotide Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Peptide and Oligonucleotide Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Peptide and Oligonucleotide Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Peptide and Oligonucleotide Drugs Sales Value Share by Type (2021-2026) Table 28. Global Peptide and Oligonucleotide Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Oncology Drugs Table 30. Significant Companies of Digestive system Drugs Table 31. Significant Companies of Immunomodulatory Drugs Table 32. Significant Companies of Bone and Connective Tissue Types Table 33. Significant Companies of Other Table 34. Global Peptide and Oligonucleotide Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Peptide and Oligonucleotide Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Peptide and Oligonucleotide Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Peptide and Oligonucleotide Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Peptide and Oligonucleotide Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Peptide and Oligonucleotide Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Peptide and Oligonucleotide Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Peptide and Oligonucleotide Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Peptide and Oligonucleotide Drugs Sales Value Share by Application (2021-2026) Table 43. Global Peptide and Oligonucleotide Drugs Sales Value Share by Application (2027-2032) Table 44. Global Peptide and Oligonucleotide Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2021-2026) Table 47. Global Peptide and Oligonucleotide Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2027-2032) Table 49. Global Peptide and Oligonucleotide Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Peptide and Oligonucleotide Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Peptide and Oligonucleotide Drugs Sales Value Share by Region (2021-2026) Table 52. Global Peptide and Oligonucleotide Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Peptide and Oligonucleotide Drugs Sales Value Share by Region (2027-2032) Table 54. Global Peptide and Oligonucleotide Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Peptide and Oligonucleotide Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Peptide and Oligonucleotide Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Peptide and Oligonucleotide Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2026) Table 60. Global Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Peptide and Oligonucleotide Drugs Sales Market Share by Country (2027-2032) Table 62. Global Peptide and Oligonucleotide Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Peptide and Oligonucleotide Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Peptide and Oligonucleotide Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Peptide and Oligonucleotide Drugs Sales Value Market Share by Country (2027-2032) Table 66. Takeda Company Information Table 67. Takeda Business Overview Table 68. Takeda Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Takeda Peptide and Oligonucleotide Drugs Product Portfolio Table 70. Takeda Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sanofi Peptide and Oligonucleotide Drugs Product Portfolio Table 75. Sanofi Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Novartis Peptide and Oligonucleotide Drugs Product Portfolio Table 80. Novartis Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Roche Peptide and Oligonucleotide Drugs Product Portfolio Table 85. Roche Recent Development Table 86. Lilly Company Information Table 87. Lilly Business Overview Table 88. Lilly Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Lilly Peptide and Oligonucleotide Drugs Product Portfolio Table 90. Lilly Recent Development Table 91. SciClone Pharmaceuticals Company Information Table 92. SciClone Pharmaceuticals Business Overview Table 93. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio Table 95. SciClone Pharmaceuticals Recent Development Table 96. Sarepta Therapeutics Company Information Table 97. Sarepta Therapeutics Business Overview Table 98. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio Table 100. Sarepta Therapeutics Recent Development Table 101. Nippon Shinyaku Company Information Table 102. Nippon Shinyaku Business Overview Table 103. Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio Table 105. Nippon Shinyaku Recent Development Table 106. Moderna Company Information Table 107. Moderna Business Overview Table 108. Moderna Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Moderna Peptide and Oligonucleotide Drugs Product Portfolio Table 110. Moderna Recent Development Table 111. MiNA Therapeutics Company Information Table 112. MiNA Therapeutics Business Overview Table 113. MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio Table 115. MiNA Therapeutics Recent Development Table 116. Merck Serono Company Information Table 117. Merck Serono Business Overview Table 118. Merck Serono Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio Table 120. Merck Serono Recent Development Table 121. Ipsen PHarma Biotech Company Information Table 122. Ipsen PHarma Biotech Business Overview Table 123. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio Table 125. Ipsen PHarma Biotech Recent Development Table 126. Ionis Company Information Table 127. Ionis Business Overview Table 128. Ionis Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Ionis Peptide and Oligonucleotide Drugs Product Portfolio Table 130. Ionis Recent Development Table 131. Ferring Pharmaceuticals Company Information Table 132. Ferring Pharmaceuticals Business Overview Table 133. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio Table 135. Ferring Pharmaceuticals Recent Development Table 136. BioNTech Company Information Table 137. BioNTech Business Overview Table 138. BioNTech Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. BioNTech Peptide and Oligonucleotide Drugs Product Portfolio Table 140. BioNTech Recent Development Table 141. AstraZeneca Company Information Table 142. AstraZeneca Business Overview Table 143. AstraZeneca Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio Table 145. AstraZeneca Recent Development Table 146. Asahi Kasei Company Information Table 147. Asahi Kasei Business Overview Table 148. Asahi Kasei Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio Table 150. Asahi Kasei Recent Development Table 151. Alnylam Company Information Table 152. Alnylam Business Overview Table 153. Alnylam Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Alnylam Peptide and Oligonucleotide Drugs Product Portfolio Table 155. Alnylam Recent Development Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Peptide and Oligonucleotide Drugs Distributors List Table 159. Peptide and Oligonucleotide Drugs Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Peptide and Oligonucleotide Drugs Product Image Figure 2. Global Peptide and Oligonucleotide Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide and Oligonucleotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peptide and Oligonucleotide Drugs Sales (2021-2032) & (K Units) Figure 5. Global Peptide and Oligonucleotide Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Peptide and Oligonucleotide Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oligonucleotide Drugs Image Figure 10. Peptide Drugs Image Figure 11. Global Peptide and Oligonucleotide Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Peptide and Oligonucleotide Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Peptide and Oligonucleotide Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Peptide and Oligonucleotide Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Peptide and Oligonucleotide Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Peptide and Oligonucleotide Drugs Sales Value Share by Type (2021-2032) Figure 17. Oncology Drugs Image Figure 18. Digestive system Drugs Image Figure 19. Immunomodulatory Drugs Image Figure 20. Bone and Connective Tissue Types Image Figure 21. Other Image Figure 22. Global Peptide and Oligonucleotide Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Peptide and Oligonucleotide Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Peptide and Oligonucleotide Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Peptide and Oligonucleotide Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Peptide and Oligonucleotide Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Peptide and Oligonucleotide Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Peptide and Oligonucleotide Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Peptide and Oligonucleotide Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Peptide and Oligonucleotide Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Peptide and Oligonucleotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Peptide and Oligonucleotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Peptide and Oligonucleotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Peptide and Oligonucleotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Peptide and Oligonucleotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Peptide and Oligonucleotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Peptide and Oligonucleotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Peptide and Oligonucleotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Peptide and Oligonucleotide Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Peptide and Oligonucleotide Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Oligonucleotide Drugs
  • Peptide Drugs
Applications
  • Oncology Drugs
  • Digestive system Drugs
  • Immunomodulatory Drugs
  • Bone and Connective Tissue Types
  • Other
Companies covered
  • Takeda
  • Sanofi
  • Novartis
  • Roche
  • Lilly
  • SciClone Pharmaceuticals
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • Moderna
  • MiNA Therapeutics
  • Merck Serono
  • Ipsen PHarma Biotech
  • Ionis
  • Ferring Pharmaceuticals
  • BioNTech
  • AstraZeneca
  • Asahi Kasei
  • Alnylam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide and Oligonucleotide Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Peptide and Oligonucleotide Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Peptide and Oligonucleotide Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peptide and Oligonucleotide Drugs Market Dynamics
  1. 2.1 Peptide and Oligonucleotide Drugs Industry Trends
  2. 2.2 Peptide and Oligonucleotide Drugs Industry Drivers
  3. 2.3 Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges
  4. 2.4 Peptide and Oligonucleotide Drugs Industry Restraints
3 Peptide and Oligonucleotide Drugs Market by Company
  1. 3.1 Global Peptide and Oligonucleotide Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Peptide and Oligonucleotide Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Peptide and Oligonucleotide Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Peptide and Oligonucleotide Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Peptide and Oligonucleotide Drugs Company Ranking (2024-2026)
  6. 3.6 Global Peptide and Oligonucleotide Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Peptide and Oligonucleotide Drugs Company Product Type and Application
  8. 3.8 Global Peptide and Oligonucleotide Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peptide and Oligonucleotide Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peptide and Oligonucleotide Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peptide and Oligonucleotide Drugs Market by Type
  1. 4.1 Peptide and Oligonucleotide Drugs Type Introduction
  2. 4.1.1 Oligonucleotide Drugs
  3. 4.1.2 Peptide Drugs
  4. 4.2 Global Peptide and Oligonucleotide Drugs Sales Volume by Type
  5. 4.2.1 Global Peptide and Oligonucleotide Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peptide and Oligonucleotide Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Peptide and Oligonucleotide Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Peptide and Oligonucleotide Drugs Sales Value by Type
  9. 4.3.1 Global Peptide and Oligonucleotide Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Peptide and Oligonucleotide Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Peptide and Oligonucleotide Drugs Sales Value Share by Type (2021-2032)
5 Peptide and Oligonucleotide Drugs Market by Application
  1. 5.1 Peptide and Oligonucleotide Drugs Application Introduction
  2. 5.1.1 Oncology Drugs
  3. 5.1.2 Digestive system Drugs
  4. 5.1.3 Immunomodulatory Drugs
  5. 5.1.4 Bone and Connective Tissue Types
  6. 5.1.5 Other
  7. 5.2 Global Peptide and Oligonucleotide Drugs Sales Volume by Application
  8. 5.2.1 Global Peptide and Oligonucleotide Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Peptide and Oligonucleotide Drugs Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Peptide and Oligonucleotide Drugs Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Peptide and Oligonucleotide Drugs Sales Value by Application
  12. 5.3.1 Global Peptide and Oligonucleotide Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Peptide and Oligonucleotide Drugs Sales Value by Application (2021-2032)
  14. 5.3.3 Global Peptide and Oligonucleotide Drugs Sales Value Share by Application (2021-2032)
6 Peptide and Oligonucleotide Drugs Regional Sales and Value Analysis
  1. 6.1 Global Peptide and Oligonucleotide Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide and Oligonucleotide Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Peptide and Oligonucleotide Drugs Sales by Region (2027-2032)
  5. 6.3 Global Peptide and Oligonucleotide Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peptide and Oligonucleotide Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peptide and Oligonucleotide Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peptide and Oligonucleotide Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Peptide and Oligonucleotide Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peptide and Oligonucleotide Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Peptide and Oligonucleotide Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peptide and Oligonucleotide Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Peptide and Oligonucleotide Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peptide and Oligonucleotide Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peptide and Oligonucleotide Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peptide and Oligonucleotide Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Peptide and Oligonucleotide Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peptide and Oligonucleotide Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peptide and Oligonucleotide Drugs Sales Value Share by Country, 2025 VS 2032
7 Peptide and Oligonucleotide Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Peptide and Oligonucleotide Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide and Oligonucleotide Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Peptide and Oligonucleotide Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Peptide and Oligonucleotide Drugs Sales by Country (2027-2032)
  6. 7.4 Global Peptide and Oligonucleotide Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peptide and Oligonucleotide Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peptide and Oligonucleotide Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peptide and Oligonucleotide Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peptide and Oligonucleotide Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peptide and Oligonucleotide Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Peptide and Oligonucleotide Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Peptide and Oligonucleotide Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Peptide and Oligonucleotide Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Roche Peptide and Oligonucleotide Drugs Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Lilly
  26. 8.5.1 Lilly Company Information
  27. 8.5.2 Lilly Business Overview
  28. 8.5.3 Lilly Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lilly Peptide and Oligonucleotide Drugs Product Portfolio
  30. 8.5.5 Lilly Recent Developments
  31. 8.6 SciClone Pharmaceuticals
  32. 8.6.1 SciClone Pharmaceuticals Company Information
  33. 8.6.2 SciClone Pharmaceuticals Business Overview
  34. 8.6.3 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
  36. 8.6.5 SciClone Pharmaceuticals Recent Developments
  37. 8.7 Sarepta Therapeutics
  38. 8.7.1 Sarepta Therapeutics Company Information
  39. 8.7.2 Sarepta Therapeutics Business Overview
  40. 8.7.3 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
  42. 8.7.5 Sarepta Therapeutics Recent Developments
  43. 8.8 Nippon Shinyaku
  44. 8.8.1 Nippon Shinyaku Company Information
  45. 8.8.2 Nippon Shinyaku Business Overview
  46. 8.8.3 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio
  48. 8.8.5 Nippon Shinyaku Recent Developments
  49. 8.9 Moderna
  50. 8.9.1 Moderna Company Information
  51. 8.9.2 Moderna Business Overview
  52. 8.9.3 Moderna Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Moderna Peptide and Oligonucleotide Drugs Product Portfolio
  54. 8.9.5 Moderna Recent Developments
  55. 8.10 MiNA Therapeutics
  56. 8.10.1 MiNA Therapeutics Company Information
  57. 8.10.2 MiNA Therapeutics Business Overview
  58. 8.10.3 MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
  60. 8.10.5 MiNA Therapeutics Recent Developments
  61. 8.11 Merck Serono
  62. 8.11.1 Merck Serono Company Information
  63. 8.11.2 Merck Serono Business Overview
  64. 8.11.3 Merck Serono Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio
  66. 8.11.5 Merck Serono Recent Developments
  67. 8.12 Ipsen PHarma Biotech
  68. 8.12.1 Ipsen PHarma Biotech Company Information
  69. 8.12.2 Ipsen PHarma Biotech Business Overview
  70. 8.12.3 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio
  72. 8.12.5 Ipsen PHarma Biotech Recent Developments
  73. 8.13 Ionis
  74. 8.13.1 Ionis Company Information
  75. 8.13.2 Ionis Business Overview
  76. 8.13.3 Ionis Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ionis Peptide and Oligonucleotide Drugs Product Portfolio
  78. 8.13.5 Ionis Recent Developments
  79. 8.14 Ferring Pharmaceuticals
  80. 8.14.1 Ferring Pharmaceuticals Company Information
  81. 8.14.2 Ferring Pharmaceuticals Business Overview
  82. 8.14.3 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
  84. 8.14.5 Ferring Pharmaceuticals Recent Developments
  85. 8.15 BioNTech
  86. 8.15.1 BioNTech Company Information
  87. 8.15.2 BioNTech Business Overview
  88. 8.15.3 BioNTech Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 BioNTech Peptide and Oligonucleotide Drugs Product Portfolio
  90. 8.15.5 BioNTech Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 Asahi Kasei
  98. 8.17.1 Asahi Kasei Company Information
  99. 8.17.2 Asahi Kasei Business Overview
  100. 8.17.3 Asahi Kasei Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio
  102. 8.17.5 Asahi Kasei Recent Developments
  103. 8.18 Alnylam
  104. 8.18.1 Alnylam Company Information
  105. 8.18.2 Alnylam Business Overview
  106. 8.18.3 Alnylam Peptide and Oligonucleotide Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Alnylam Peptide and Oligonucleotide Drugs Product Portfolio
  108. 8.18.5 Alnylam Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide and Oligonucleotide Drugs Value Chain Analysis
  2. 9.1.1 Peptide and Oligonucleotide Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide and Oligonucleotide Drugs Sales Mode & Process
  6. 9.2 Peptide and Oligonucleotide Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide and Oligonucleotide Drugs Distributors
  9. 9.2.3 Peptide and Oligonucleotide Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst